Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: Results of the PROMISSE study

American Journal of Obstetrics and Gynecology

Volumn 214, Issue 1, 2016, Pages 108.e1-108.e14

  Kim, Mimi Y ^a   Buyon, Jill P ^b   Guerra, Marta M ^c   Rana, Sarosh ^d   Zhang, Dongsheng ^d   Laskin, Carl A ^e   Petri, Michelle ^f   Lockshin, Michael D ^c,g   Sammaritano, Lisa R ^c,g   Branch, D Ware ^h   Porter, T Flint ^h   Merrill, Joan T ⁱ   Stephenson, Mary D ^j   Gao, Qi ^a   Karumanchi, S Ananth ^d   Salmon, Jane E ^c,g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

ⁱ UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

angiogenic factors; antiphospholipid antibodies; placental insufficiency; preeclampsia; systemic lupus erythematosus

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; HEPARIN; LEUKOCYTE ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PGF PROTEIN, HUMAN; PLACENTA PROTEIN;

ADULT; ADVERSE OUTCOME; ARTICLE; DISEASE SEVERITY; FEMALE; FETUS DEATH; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; NEWBORN DEATH; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CLINICAL TRIAL; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HIGH RISK PREGNANCY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTICENTER STUDY; PREGNANCY; PROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIGENS, CD; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; BIOMARKERS; ENDOGLIN; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HEPARIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY, HIGH-RISK; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84955508652     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2015.09.066     Document Type: Article

References (44)

1. M. Petri, and J. Allbritton Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort J Rheumatol 20 1993 650 656
2. P.E. Georgiou, E.N. Politi, P. Katsimbri, V. Sakka, and A.A. Drosos Outcome of lupus pregnancy: a controlled study Rheumatology (Oxford) 39 2000 1014 1019
3. M.E. Clowse, M. Jamison, E. Myers, and A.H. James A national study of the complications of lupus in pregnancy Am J Obstet Gynecol 199 2008 127.e1 127.e6
4. J.P. Buyon, M.Y. Kim, M.M. Guerra, and et al. Predictors of pregnancy outcome in a prospective, multiethnic cohort of lupus patients: a cohort study Ann Intern Med 163 2015 163-63
5. R. Pijnenborg, L. Vercruysse, and M. Hanssens The uterine spiral arteries in human pregnancy: facts and controversies Placenta 27 2006 939 958
6. J.M. Roberts, and C.A. Hubel The two stage model of preeclampsia: variations on the theme Placenta 30 Suppl 2009 S32 S37
7. G.J. Burton, A.W. Woods, E. Jauniaux, and J.C. Kingdom Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy Placenta 30 2009 473 482
8. B.C. Young, R.J. Levine, and S.A. Karumanchi Pathogenesis of preeclampsia Annu Rev Pathol 5 2010 173 192
9. Y. Zhou, C.H. Damsky, and S.J. Fisher Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 99 1997 2152 2164
10. S.E. Maynard, J.Y. Min, J. Merchan, and et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 2003 649 658
11. R.J. Levine, S.E. Maynard, C. Qian, and et al. Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 2004 672 683
12. A.S. Maharaj, T.E. Walshe, M. Saint-Geniez, and et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma J Exp Med 205 2008 491 501
13. F. Lu, M. Longo, E. Tamayo, and et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice Am J Obstet Gynecol 196 2007 396.e1 396.e7
14. R.J. Levine, C. Lam, C. Qian, and et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 2006 992 1005
15. J.P. Kusanovic, R. Romero, T. Chaiworapongsa, and et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia J Matern Fetal Neonatal Med 22 2009 1021 1038
16. M. Noori, A.E. Donald, A. Angelakopoulou, A.D. Hingorani, and D.J. Williams Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension Circulation 122 2010 478 487
17. I. Herraiz, L.A. Droge, E. Gomez-Montes, W. Henrich, A. Galindo, and S. Verlohren Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction Obstet Gynecol 124 2014 265 273
18. B.O. Asvold, L.J. Vatten, P.R. Romundstad, P.A. Jenum, S.A. Karumanchi, and A. Eskild Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction Am J Epidemiol 173 2011 630 639
19. R. Romero, T. Chaiworapongsa, O. Erez, and et al. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study J Matern Fetal Neonatal Med 23 2010 1384 1399
20. A.E. Whitten, R. Romero, S.J. Korzeniewski, and et al. Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death Am J Obstet Gynecol 208 2013 310.e1 310.e11
21. T. Chaiworapongsa, R. Romero, S.J. Korzeniewski, and et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia Am J Obstet Gynecol 208 2013 287.e1 287.e15
22. M.C. Hochberg Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 40 1997 1725
23. M.D. Lockshin, M. Kim, C.A. Laskin, and et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies Arthritis Rheum 64 2012 2311 2318
24. S. Miyakis, M.D. Lockshin, T. Atsumi, and et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 4 2006 295 306
25. ACOG Committee on Practice Bulletins-Obstetrics Diagnosis and management of preeclampsia and eclampsia. ACOG Practice bulletin no. 33, January 2002 Obstet Gynecol 99 2002 159 167
26. R. Romero, J.K. Nien, J. Espinoza, and et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate J Matern Fetal Neonatal Med 21 2008 9 23
27. J. Fleiss, B. Levin, and M. Paik Statistical methods for rates and proportions 3rd ed. 2003 John Wiley and Sons Inc Hoboken (NJ)
28. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
29. K.G. Moons, D.G. Altman, J.B. Reitsma, and et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration Ann Intern Med 162 2015 W1 73
30. A.J. Vickers, A.M. Cronin, and C.B. Begg One statistical test is sufficient for assessing new predictive markers BMC Med Res Methodol 11 2011 13
31. G.R. de Jesus, G. Rodrigues, N.R. de Jesus, and R.A. Levy Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep 16 2014 403
32. H. Hagmann, V. Bossung, A.A. Belaidi, and et al. Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination PLoS One 9 2014 e85258
33. J. Searle, M. Mockel, S. Gwosc, and et al. Heparin strongly induces soluble fms-like tyrosine kinase 1 release in vivo and in vitro-brief report Arterioscler Thromb Vasc Biol 31 2011 2972 2974
34. C. Li, N.S. Raikwar, M.K. Santillan, D.A. Santillan, and C.P. Thomas Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1 Placenta 36 2015 446 453
35. U. Qazi, C. Lam, S.A. Karumanchi, and M. Petri Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus J Rheumatol 35 2008 631 634
36. M.A. Rodger, M. Carrier, G. Le Gal, and et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications Blood 123 2014 822 828
37. M.L. LeFevre US Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: US Preventive Services Task Force recommendation statement Ann Intern Med 161 2014 819 826
38. A.M. Schramm, and M.E. Clowse Aspirin for prevention of preeclampsia in lupus pregnancy Autoimmune Dis 2014 2014 920467
39. G. Girardi, J. Berman, P. Redecha, and et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome J Clin Invest 112 2003 1644 1654
40. G. Girardi, D. Yarilin, J.M. Thurman, V.M. Holers, and J.E. Salmon Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction J Exp Med 203 2006 2165 2175
41. J. Berman, G. Girardi, and J.E. Salmon TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss J Immunol 174 2005 485 490
42. D. Andrade, M. Kim, L.P. Blanco, and et al. Interferon-alpha and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia Arthritis Rheumatol 67 2015 977 987
43. S.G. Thacker, C.C. Berthier, D. Mattinzoli, M.P. Rastaldi, M. Kretzler, and M.J. Kaplan The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction J Immunol 185 2010 4457 4469
44. S.E. Gelber, E. Brent, P. Redecha, and et al. Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency J Immunol 195 2015 1129 1138